Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

dard of care."

The Phase 3 study was designed to compare the safety and efficacy of motavizumab with that of Synagis, which was first launched by MedImmune in 1998, in reducing serious RSV disease in high-risk infants in the inpatient and outpatient settings. As defined in the study, infants who are at high risk for RSV include those who were born at 35 weeks gestation or less as well as those who have chronic lung disease (CLD) due to being born prematurely. The primary endpoint was to assess the incidence of RSV hospitalizations with motavizumab compared to Synagis. Motavizumab met the primary endpoint, demonstrating non-inferiority to Synagis with 26 percent fewer RSV hospitalizations in motavizumab-treated infants. The overall RSV attack rate was low in both treatment groups: 1.4 percent for infants who received motavizumab, compared with 1.9 percent for those who received Synagis [RR: 0.740, 95 percent CI: (0.503, 1.083)]. The p-value for non-inferiority was p<0.01, demonstrating a significant finding.

Analysis of the data also showed that motavizumab reduced the incidence of RSV-specific medically attended outpatient LRIs (the study's RSV-related secondary endpoint) by approximately 50 percent compared with Synagis. The overall RSV-specific medically attended LRI rate was 2.0 percent for infants who received motavizumab compared with 3.9 percent for those who received Synagis (p<0.01). There were no significant differences in other non-RSV- specific endpoints.

"I am very pleased with the study results for motavizumab," said Xavier Carbonell, M.D., Ph.D., lead study author, chairman of neonatology, Barcelona Hospital Clinic, and vice president, Spanish Neonatal Society. "As a practicing neonatologist, I look forward to the potential to use this next- generation antibody to help reduce RSV-related hospitalizations and LRIs in the outpatient setting."

Data from this trial demonstrate that both study drugs were well tolerated. The incid
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:4/27/2015)... MILAN , April 27, 2015  USL di ... Italian province of Reggio Emilia, has implemented Zebra ... throughout the hospital. The Wireless Network Solution ... patients, medical records securely and in real time via ... available at all times. Zebra also provides employee and ...
(Date:4/27/2015)... SAN DIEGO , April 27, 2015  Agena Bioscience ... (CSP) for Agena Bioscience,s MassARRAY platform in China ... at unprecedented speed. It is a hotbed for practical, meaningful ... China and for the rest of the world. ... community in China ," said Peter ...
(Date:4/27/2015)... -- China Jo-Jo Drugstores, Inc. (NASDAQ CM: ... leading China-based retail and wholesale distributor that offers pharmaceutical ... pharmacies, today announced its subsidiary, Hangzhou Jiuzhou Grand Pharmacy ... sales incentive agreement with Wyeth Pharmaceutical Company, Ltd. ("Wyeth"), ... of Pfizer Inc. (NYSE: PFE ) (the ...
Breaking Medicine Technology:Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 4Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 5Agena Bioscience Names Bioyong Technology as Fifth Certified Service Provider in China 2China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 2China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 3China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 4
... Disease Week ... 2008, ... today that it has initiated the Phase 2 clinical,development program of MDX-1100, ... ulcerative colitis (UC) and,rheumatoid arthritis (RA). MDX-1100 could potentially treat UC and ...
... Thailand, May 9 An emergency,veterinary team from the ... stand-by in Thailand awaiting authority to enter cyclone struck,Myanmar ... of animals,that human survivors depend on for food and ... The Food and Agriculture,Organization of the United Nations (FAO) ...
Cached Medicine Technology:Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 2Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 3Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 4Animals That Cyclone Survivors Depend on Need Help Now 2
(Date:4/27/2015)... On April 16, 2015, Harper’s Bazaar Magazine, in ... Marks ,” interviewed a UK dermatologist on the causes and ... are a type of scar that reportedly affects nearly 90% ... of the elsastin and collagen in the dermis, the dense ... mark removal with the Coolbeam protocol is one of our ...
(Date:4/27/2015)... 2015 Beckman Coulter is sponsoring a ... study the evolution of neural circuitry and swimming behavior ... the mechanisms by which analogous forms of swimming behavior, ... evolved independently in certain sea slug clades. The webinar ... April 30, 2015 at 8:00am PT. , Sea slugs ...
(Date:4/27/2015)... Humble, TX (PRWEB) April 27, 2015 Sitting ... legs to ache and feel tired, and for those whose ... such as receptionists and taxi cab drivers, or to be ... teachers and hairdressers, the discomfort can be more severe and ... tired, achy leg syndrome. Dr. Madaiah Revana of Northeast Houston ...
(Date:4/27/2015)... PA (PRWEB) April 27, 2015 FMC ... will exhibit its wide range of market leading ingredients ... May 7 in Geneva, Switzerland. Vitafoods Europe 2015 expects ... 100 countries showcasing the latest research in such areas ... nutrition. , FMC Health and Nutrition’s booth will ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Telematics Berlin ... tier 1&2 suppliers, associations, CE players and the government ... has opened to the car. This year’s panel on ... DG-Move at the European Commission, is an opportunity to ... and define a European Automotive Security Standard for years ...
Breaking Medicine News(10 mins):Health News:Stretch Marks: The Latest Treatment Options for Stretch Mark Removal 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 3Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 3Health News:FMC Health and Nutrition to Feature Epax® Brand Omega-3 Ingredients at Vitafoods Europe 2015 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 3
... 25 Smart Balance Inc.,(Nasdaq: SMBL ) will ... on Wednesday, May 21, 2008, at the Teaneck Marriott ... 07666. Stockholders of record,at the close of business on ... all matters that properly come before the meeting., ...
... passed the Genetic Information Nondiscrimination Act (GINA) on April 24, ... which passed the House April 25, 2007 by a vote ... measure again quickly before sending it to President Bush to ... wait, Americans can now be confident that their genetic information ...
... A Johns Hopkins University biologist, in research with implications ... has determined that the eye uses light to reset ... ability to see. , The findings suggest that patients ... can be linked to lack of exposure to daylight ...
... InfoLogix, Inc.,(Nasdaq: IFLG ), a leading technology ... commercial industries, will release its,financial results for the ... 30th, 2008. Following the press release, President and ... Jay Roberts will,host a conference call with the ...
... had less blood loss, shorter hospital stays, study finds ... laparoscopic surgery to remove pancreatic tumors or cysts leads ... study finds. , In laparoscopic surgery, doctors make ... progress with fiber optics and video cameras. This less ...
... (OTC Bulletin,Board: NTRZ), a world leader in stabilized ... that it has entered into,definitive agreements to sell ... of $20,000,000. The offering is made,pursuant to the ... by,NutraCea with the Securities and Exchange Commission (the ...
Cached Medicine News:Health News:Genetic Information Nondiscrimination Act clears Senate 2Health News:Different processes govern sight, light detection 2Health News:InfoLogix to Report First Quarter Results on April 30, 2008 2Health News:Laparoscopic Surgery on Pancreas Has Fewer Complications 2Health News:NutraCea Announces $20 Million Securities Offering 2Health News:NutraCea Announces $20 Million Securities Offering 3
Inquire...
Inquire...
Inquire...
The modular, high-end stereomicroscope; meets even the most critical demands in research and quality control provides high-contrast images with excellent depth of field and color fidelity...
Medicine Products: